Compare Charles River Laboratories Intl. Inc (CRL) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Workday Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Workday Inc trades at $174.51 (market cap $44.77B). The key difference: Workday Inc is far larger — about 3.3× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Workday Inc nearer its low. Which is the better fit depends on your goals.
| CRL | WDAY | |
|---|---|---|
Market Cap | $13.46B | $44.77B |
Sector | Health | Technology |
52-Week High | $282.00 | $247.69 |
52-Week Low | $145.57 | $112.55 |
Enterprise Value | $16.30B | $44.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
Workday (WDAY) trades at $174.53, down 5.24% today but maintains strong technical momentum with bullish moving averages. The company demonstrates robust revenue growth, reaching $8.45B in 2025 with consistent earnings beats. Recent partnerships and AI product launches, including Workday Learning and FedRAMP authorization, highlight strategic expansion. Analyst consensus remains positive with 55.6% buy ratings despite a recent downgrade from Morgan Stanley on July 21, 2026.
WDAY's outlook is supported by solid fundamentals and AI-driven growth initiatives, though elevated valuation metrics (P/E 56.47) and institutional selling pose risks. The stock faces near-term pressure from overbought technical indicators but maintains long-term potential through enterprise software demand and market leadership in HR/finance solutions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
